Search Results

You are looking at 111 - 120 of 149 items for :

  • "prostate-specific antigen" x
  • Refine by Access: All x
Clear All
Full access

Models of Care and NCCN Guideline Adherence in Very-Low-Risk Prostate Cancer

Ayal A. Aizer, Jonathan J. Paly, Anthony L. Zietman, Paul L. Nguyen, Clair J. Beard, Sandhya K. Rao, Irving D. Kaplan, Andrzej Niemierko, Michelle S. Hirsch, Chin-Lee Wu, Aria F. Olumi, M. Dror Michaelson, Anthony V. D’Amico, and Jason A. Efstathiou

Design and Patient Population The authors identified 630 consecutive patients with low-risk prostate cancer (Gleason score ≤6, pretreatment prostate-specific antigen [PSA] <10, and clinical stage of ≤T2a) managed at 1 of 3 academic hospitals affiliated

Full access

Survivorship: Nutrition and Weight Management, Version 2.2014

Crystal S. Denlinger, Jennifer A. Ligibel, Madhuri Are, K. Scott Baker, Wendy Demark-Wahnefried, Don Dizon, Debra L. Friedman, Mindy Goldman, Lee Jones, Allison King, Grace H. Ku, Elizabeth Kvale, Terry S. Langbaum, Kristin Leonardi-Warren, Mary S. McCabe, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Mary Ann Morgan, Javid J. Moslehi, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, Muhammad Raza, M. Alma Rodriguez, Karen L. Syrjala, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass

. Ho T Gerber L Aronson WJ . Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database . Eur Urol 2012 ; 62 : 910 – 916 . 15. Imayama I Alfano

Full access

Complexities of Next-Generation Sequencing in Solid Tumors: Case Studies

Alexandra O. Sokolova, Brian H. Shirts, Eric Q. Konnick, Ginger J. Tsai, Bernardo H.L. Goulart, Bruce Montgomery, Colin C. Pritchard, Evan Y. Yu, and Heather H. Cheng

76-year-old man with high-risk localized prostate cancer (cT2b; Gleason score 4 + 4 = 8; prostate-specific antigen [PSA] level, 9.1 ng/mL). This patient’s family history was notable for an older sister diagnosed with breast cancer at age 73 years and

Full access

Outcomes of Patients With Unfavorable Intermediate-Risk Prostate Cancer Treated With External-Beam Radiotherapy Versus Brachytherapy Alone

Neal Andruska, Benjamin W. Fischer-Valuck, Ruben Carmona, Temitope Agabalogun, Randall J. Brenneman, Hiram A. Gay, Jeff M. Michalski, and Brian C. Baumann

included who met criteria for UIR prostate cancer, defined as intermediate-risk disease and either primary Gleason 4 disease, diffuse disease (≥50% biopsy cores positive), or 2 of 3 intermediate-risk factors (cT2b–T2c; prostate-specific antigen [PSA] level

Full access

Integrated Histogenetic Analysis Reveals BAP1-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary

Tilmann Bochtler, Volker Endris, Anna Reiling, Jonas Leichsenring, Michal R. Schweiger, Sebastian Klein, Fabian Stögbauer, Benjamin Goeppert, Peter Schirmacher, Alwin Krämer, and Albrecht Stenzinger

, chromogranin A, TTF1, napsin, CDX2, CK20, HMB45, melan A, CD34, CD45R (LCA), prostate-specific antigen, and androgen receptor ( Figure 1A–H ). For BAP1 immunohistochemistry, a mouse monoclonal antibody (clone C-4) against amino acids 430 to 729 (Santa Cruz

Full access

Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients

Lara Franziska Stolzenbach, Giuseppe Rosiello, Angela Pecoraro, Carlotta Palumbo, Stefano Luzzago, Marina Deuker, Zhe Tian, Anne-Sophie Knipper, Raisa Pompe, Kevin C. Zorn, Shahrokh F. Shariat, Felix K.H. Chun, Markus Graefen, Fred Saad, and Pierre I. Karakiewicz

obtained from the SEER database for the period 2010 through 2015. 4 We focused on patients with histologically confirmed nonmetastatic adenocarcinoma of the prostate (ICD-O C61.9) who had available prostate-specific antigen (PSA) values and were treated

Full access

The Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients With Prostate Cancer

Nicola Fossati, Daniel P. Nguyen, Quoc-Dien Trinh, Jesse Sammon, Akshay Sood, Alessandro Larcher, Giorgio Guazzoni, Francesco Montorsi, Alberto Briganti, Mani Menon, and Firas Abdollah

were individuals with unknown prostate-specific antigen (PSA) levels (n=5,345), clinical stage (n=204), biopsy Gleason score (n=739), percentage of positive cores (n=17,551), race (n=500), marital status (n=1,796), or insurance status (n=1,087). These

Full access

Impact of Prostate Cancer Diagnosis on Noncancer Hospitalizations Among Elderly Medicare Beneficiaries With Incident Prostate Cancer

Amit D. Raval, Suresh Madhavan, Malcolm D. Mattes, Mohamad Salkini, and Usha Sambamoorthi

cancer: patterns of care and early toxicity . J Natl Cancer Inst 2013 ; 105 : 25 – 32 . 15. Trantham LC Nielsen ME Mobley LR . Use of prostate-specific antigen testing as a disease surveillance tool following radical prostatectomy . Cancer

Full access

Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States

Ayal A. Aizer, Xiangmei Gu, Ming-Hui Chen, Toni K. Choueiri, Neil E. Martin, Jason A. Efstathiou, Andrew S. Hyatt, Powell L. Graham, Quoc-Dien Trinh, Jim C. Hu, and Paul L. Nguyen

benefit to prostatectomy versus observation in patients with low-risk disease. 6 In recommending against prostate-specific antigen (PSA) screening for prostate cancer, the US Preventative Services Task Force (USPSTF) described overtreatment of indolent

Full access

Guideline Familiarity Predicts Variation in Self-Reported Use of Routine Surveillance PET/CT by Physicians Who Treat Head and Neck Cancer

Benjamin R. Roman, Snehal G. Patel, Marilene B. Wang, Anna M. Pou, F. Christopher Holsinger, David Myssiorek, David Goldenberg, Samuel Swisher-McClure, Alexander Lin, Jatin P. Shah, and Judy A. Shea

address overuse . JAMA 2013 ; 309 : 1897 – 1898 . 18. Kerfoot BP Holmberg EF Lawler EV . Practitioner-level determinants of inappropriate prostate-specific antigen screening . Arch Intern Med 2007 ; 167 : 1367 – 1372 . 19. Ong